TALEN-Based Gene Correction for RDEB
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy tools for conditions like Recessive Dystrophic Epidermolysis Bullosa (RDEB) face challenges due to random integration of therapeutic genes, leading to off-target effects and life-threatening side effects, as they integrate at random or semi-random locations in the genome, causing perturbation and potential gene inactivation or dysregulation.
Innovation Solution
The use of engineered transcription activator-like effector nucleases (TALENs) for site-specific genome editing, which induce precise double-stranded DNA breaks in target genes, allowing for site-specific correction of mutations using a donor sequence as a template for DNA repair, thereby avoiding random integration and minimizing off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral-mediated gene-addition therapy is used to treat genetic disorders, then functional copies of therapeutic genes are provided to patients, but random integration into the genome causes perturbation of the locus where the cargo lands and potential gene inactivation or dysregulation (off target effects)
Solution Approach 1:
The patent applies preliminary action by using TALEN proteins to create site-specific double-stranded DNA breaks at the target mutation location before introducing the donor sequence. This pre-prepared break at the exact desired location ensures that subsequent DNA repair incorporates the corrective sequence precisely where needed, rather than random integration. The TALEN-mediated cleavage occurs beforehand to guide the repair mechanism to the correct genomic position.
Solution Approach 2:
The patent uses TALEN proteins as intermediaries to mediate between the therapeutic goal and the genome. The TALEN complex serves as a bridge that recognizes the specific target sequence through its DNA-binding domain and facilitates precise editing through its nuclease activity. This intermediary mechanism enables controlled, site-specific modification without random integration, resolving the contradiction between therapeutic effectiveness and off-target effects.
2Reliability
If random integration of therapeutic genes occurs, then gene augmentation is achieved, but life threatening side effects result from insertional mutagenesis
Solution Approach 1:
The patent applies local quality by making the DNA breakage and repair process location-specific through TALEN proteins. The TALEN system confers different functional properties to different locations in the genome - the target site receives precise editing capability while other regions remain unaffected. This localized action ensures that gene augmentation occurs only at the intended mutation site, preventing insertional mutagenesis in other genomic locations.
Solution Approach 2:
The patent uses preliminary action by pre-targeting the specific mutation site with TALEN proteins before introducing the corrective donor sequence. The TALEN-mediated DNA break is created beforehand at the exact location requiring correction, ensuring that the subsequent repair process occurs only at this predetermined site. This preliminary site-specific preparation prevents random integration and associated insertional mutagenesis.
3Manufacturing precision
If site-specific correction of mutation is performed using TALEN, then off target effects are overcome and precise DNA editing is achieved, but complex delivery systems and precise targeting are required
Solution Approach 1:
The patent applies segmentation by dividing the TALEN system into modular components - the TALE repeat array for DNA recognition and the FokI nuclease domain for cleavage. These modular elements can be independently designed and assembled to target specific sequences. The segmentation of the therapeutic approach into TALEN delivery followed by donor sequence introduction allows precise control over the editing process while managing system complexity through modular design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables safe and effective correction of genetic mutations, restoring normal gene expression and protein function, while minimizing disruption to the remaining genome, thus reducing the risk of life-threatening side effects and enhancing gene expression.
Implementation Method 1
TALEN protein is expressed in the cell and induces a site-specific double stranded DNA break in a target gene
Implementation Method 2
the donor sequence is a template for DNA repair resulting in a correction of the genetic mutation
Data Source
Figure 1A~1F
Figure 2
Figure 3A~3C
AI summary
The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders. Epidermolysis bullosa (EB) is a group of genetic conditions that cause the skin to be very fragile and to blister easily. Blisters and skin erosions form in response to minor injury or friction, such as rubbing or scratching. Recessive dystrophic epidermolysis bullosa (RDEB), the most severe and classical form of the disease, is characterized by extensive blistering and scarring of the skin and mucosal membranes.